Dynamic Technology Lab Private Ltd Sells 16,760 Shares of Encompass Health Corporation $EHC

Key Points

• Dynamic Technology Lab Private Ltd reduced its stake in Encompass Health Corporation by 76.4%, selling 16,760 shares and holding 5,180 shares valued at $525,000 after the sale.
• Encompass Health has increased its quarterly dividend from $0.17 to $0.19 per share, highlighting a 0.6% yield with a payout ratio of 13.31%.
• Analysts have raised their price targets for Encompass Health, with Bank of America setting a new target at $160.00 and most analysts issuing a "Buy" rating for the stock.

Dynamic Technology Lab Private Ltd cut its holdings in Encompass Health Corporation (NYSE:EHC - Free Report) by 76.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 5,180 shares of the company's stock after selling 16,760 shares during the period. Dynamic Technology Lab Private Ltd's holdings in Encompass Health were worth $525,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in EHC. Invesco Ltd. lifted its holdings in Encompass Health by 5.1% in the first quarter. Invesco Ltd. now owns 5,818,783 shares of the company's stock worth $589,326,000 after acquiring an additional 282,532 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Encompass Health by 25.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company's stock worth $210,756,000 after purchasing an additional 424,691 shares during the period. Dimensional Fund Advisors LP boosted its stake in Encompass Health by 5.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,871,581 shares of the company's stock worth $189,549,000 after buying an additional 93,992 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Encompass Health by 13.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,822,376 shares of the company's stock worth $184,571,000 after acquiring an additional 211,707 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its holdings in Encompass Health by 11.9% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,541,477 shares of the company's stock valued at $156,121,000 after acquiring an additional 163,400 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.

Encompass Health Trading Down 0.6%

Shares of Encompass Health stock traded down $0.76 during trading on Friday, reaching $126.04. The company's stock had a trading volume of 551,583 shares, compared to its average volume of 633,963. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 52-week low of $87.85 and a 52-week high of $127.15. The firm's 50-day moving average is $117.50 and its two-hundred day moving average is $112.76. The company has a market cap of $12.70 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 2.22 and a beta of 0.92.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.20. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The company's revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.11 earnings per share. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. On average, sell-side analysts anticipate that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be given a $0.19 dividend. The ex-dividend date is Wednesday, October 1st. This is a positive change from Encompass Health's previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. Encompass Health's dividend payout ratio is presently 14.87%.

Insider Buying and Selling at Encompass Health

In other news, EVP Patrick William Tuer sold 1,020 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the transaction, the executive vice president directly owned 18,846 shares of the company's stock, valued at approximately $2,329,177.14. The trade was a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.00% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on EHC shares. Stephens upgraded shares of Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price objective for the company in a research note on Thursday, June 5th. Bank of America raised their price target on shares of Encompass Health from $145.00 to $160.00 and gave the company a "buy" rating in a research note on Wednesday. KeyCorp raised their price target on shares of Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a report on Tuesday, May 27th. Truist Financial upped their target price on Encompass Health from $135.00 to $140.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Finally, Wall Street Zen lowered shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $137.71.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.